- In May 2025, Johnson & Johnson's Janssen Pharmaceuticals announced that Tremfya (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis. This approval, based on clinical trials, shows significant improvement in joint symptoms, skin lesions, and patient-reported outcomes. Tremfya offers a new option for patients with treatment-resistant active psoriatic arthritis, aiming to improve patient quality of life and expand the treatment landscape. It is expected to make a significant impact in the market due to its unique mechanism of action and effectiveness
- In August 2021, Seikagaku Corporation launched HyLink, a single-injection viscosupplement for knee osteoarthritis in Taiwan. Developed using proprietary cross-linking technology, HyLink offers long-lasting relief with a single 3 mL injection. The product complements Seikagaku’s existing portfolio, including ARTZDispo and Artzfors. This launch strengthens Seikagaku's position in Taiwan, addressing the rising demand for effective osteoarthritis treatments, especially among the aging population
